TERN | Terns Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.04 - 7.99
52 Week Range	3.26 - 10.03
Beta	0.04
Implied Volatility	266.36%
IV Rank	92.74%
Day's Volume	1,338,874
Average Volume	1,197,995
Shares Outstanding	70,371,900
Market Cap	549,604,539
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	-5.92
Forward P/E Ratio	N/A
EPS	-1.32
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	66
Country	USA
Website	TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

TERN's peers: ABEO, ABOS, ACAD, AFMD, AKRO, ALDX, ALT, ALZN, AMLX, ANVS, APLS, APLT, ARDX, ARGX, ARQT, ARWR, AUPH, AUTL, AXSM, BBIO, BCLI, BCTX, BHVN, BIVI, BLRX, BPMC, BTAI, CERE, CMRX, CNTX, CPRX, CRIS, CRVS, CTXR, CUE, CYTK, DAWN, DMAC, DTIL, ELDN, ETNB, EYPT, GALT, GLSI, GLTO, GMAB, GOSS, GNLX, HOOK, HRTX, IDYA, INKT, INVA, INZY, IONS, ITOS, LEGN, LGND, LPTX, LQDA, LXRX, MDGL, MEIP, MESO, MIRM, MIST, MORF, MREO, MRNS, MRSN, NERV, NVO, OCUL, ONCY, ORMP, OTLK, PDSB, PHAT, PIRS, PRQR, PTGX, PYXS, QURE, RARE, RIGL, RLAY, RVNC, SAGE, SANA, SPRB, SRPT, SWTX, TCRX, XFOR, TGTX, TSHA, VCEL, VIR, VIRX, VKTX, VRDN, VRNA, VYGR, WVE, XERS, ZYME, MLTX, IRON, COYA, GPCR

*Chart delayed

Analyzing fundamentals for TERN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see TERN Fundamentals page.

Watching at TERN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on TERN Technicals page.